Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Glionova Therapeutics raises financing for clinical development of glioblastoma candidate

Nov. 14, 2014

Novel anti-PD-L1 therapy shows promise in in vitro and in vivo bladder tumor models

Nov. 13, 2014

Oncothyreon and Celldex start phase I trial of MUC1 vaccine and anti-CD27 antibody combination

Nov. 11, 2014

AVEO Pharma designs anti-Notch 1 MAbs

Nov. 11, 2014

Kancera selects first candidate in ROR project

Nov. 5, 2014

Altor BioScience begins development of ALT-803 for multiple myeloma

Nov. 5, 2014

arGEN-X files IND to begin study of ARGX-110 in Waldenstrom's macroglobulinemia

Nov. 4, 2014

Glioma candidate pritumumab receives U.S. orphan drug designation

Nov. 3, 2014

Kurume University discloses new cancer antigen peptide vaccines

Oct. 29, 2014

Biothera announces phase Ib trial of mucin-1-targeted antibody BTH-1704 and Imprime PGG

Oct. 28, 2014

Popular Stories

Today's news in brief
BioWorld
MMP inhibitors divulged in Accure Therapeutics patent
BioWorld Science
Accure Therapeutics has reported new oligopeptide derivatives acting as matrix metalloproteinase-2 (MMP-2) and MMP-9 inhibitors. As such, they are described as...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 14, 2026
MSD discloses new HCN1/2 blockers
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...
Selective CBL-B inhibitor with improved safety profile disclosed
BioWorld Science
CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...